209 related articles for article (PubMed ID: 24403261)
1. Oncologists' attitudes toward KRAS testing: a multisite study.
Harris JN; Liljestrand P; Alexander GL; Goddard KA; Kauffman T; Kolevska T; McCarty C; O'Neill S; Pawloski P; Rahm A; Williams A; Somkin CP
Cancer Med; 2013 Dec; 2(6):881-8. PubMed ID: 24403261
[TBL] [Abstract][Full Text] [Related]
2. Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.
Han van Krieken J; Kafatos G; Bennett J; Mineur L; Tomášek J; Rouleau E; Fabian P; De Maglio G; García-Alfonso P; Aprile G; Parkar P; Downey G; Demonty G; Trojan J
BMC Cancer; 2017 Nov; 17(1):798. PubMed ID: 29183279
[TBL] [Abstract][Full Text] [Related]
3. Should oncologists be aware in their clinical practice of KRAS molecular analysis?
Santini D; Galluzzo S; Gaeta L; Zoccoli A; Riva E; Ruzzo A; Vincenzi B; Graziano F; Loupakis F; Falcone A; Muda AO; Tonini G
J Clin Oncol; 2011 Mar; 29(8):e206-7; author reply e208-9. PubMed ID: 21263083
[No Abstract] [Full Text] [Related]
4. Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
Landsman-Blumberg PB; Carter GC; Johnson BH; Sedgley R; Nicol SJ; Li L; Shankaran V
Clin Colorectal Cancer; 2014 Sep; 13(3):178-84. PubMed ID: 25065655
[TBL] [Abstract][Full Text] [Related]
5. KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting.
Barone C; Pinto C; Normanno N; Capussotti L; Cognetti F; Falcone A; Mantovani L
PLoS One; 2014; 9(1):e85897. PubMed ID: 24465771
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach.
Domagała P; Hybiak J; Sulżyc-Bielicka V; Cybulski C; Ryś J; Domagała W
Pol J Pathol; 2012 Nov; 63(3):145-64. PubMed ID: 23161231
[TBL] [Abstract][Full Text] [Related]
7. Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective.
Ross JS
Arch Pathol Lab Med; 2012 Oct; 136(10):1298-307. PubMed ID: 22272560
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine.
Wang HL; Lopategui J; Amin MB; Patterson SD
Adv Anat Pathol; 2010 Jan; 17(1):23-32. PubMed ID: 20032635
[TBL] [Abstract][Full Text] [Related]
9. Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience.
Blons H; Rouleau E; Charrier N; Chatellier G; Côté JF; Pages JC; de Fraipont F; Boyer JC; Merlio JP; Morel A; Gorisse MC; de Cremoux P; Leroy K; Milano G; Ouafik L; Merlin JL; Le Corre D; Aucouturier P; Sabourin JC; Nowak F; Frebourg T; Emile JF; Durand-Zaleski I; Laurent-Puig P;
PLoS One; 2013; 8(7):e68945. PubMed ID: 23935912
[TBL] [Abstract][Full Text] [Related]
10. Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.
Trojan J; Mineur L; Tomášek J; Rouleau E; Fabian P; de Maglio G; García-Alfonso P; Aprile G; Taylor A; Kafatos G; Downey G; Terwey JH; van Krieken JH
PLoS One; 2015; 10(10):e0140717. PubMed ID: 26491871
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.
Shiroiwa T; Motoo Y; Tsutani K
Mol Diagn Ther; 2010 Dec; 14(6):375-84. PubMed ID: 21275455
[TBL] [Abstract][Full Text] [Related]
12. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer.
Huang CW; Tsai HL; Chen YT; Huang CM; Ma CJ; Lu CY; Kuo CH; Wu DC; Chai CY; Wang JY
BMC Cancer; 2013 Dec; 13():599. PubMed ID: 24330663
[TBL] [Abstract][Full Text] [Related]
13. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
Behl AS; Goddard KA; Flottemesch TJ; Veenstra D; Meenan RT; Lin JS; Maciosek MV
J Natl Cancer Inst; 2012 Dec; 104(23):1785-95. PubMed ID: 23197490
[TBL] [Abstract][Full Text] [Related]
15. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?
Scott RJ; Fox SB; Desai J; Grieu F; Amanuel B; Garrett K; Harraway J; Cheetham G; Pattle N; Haddad A; Byron K; Rudzki B; Waring P; Iacopetta B
Asia Pac J Clin Oncol; 2014 Sep; 10(3):261-5. PubMed ID: 24811330
[TBL] [Abstract][Full Text] [Related]
17. RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.
Lièvre A; Merlin JL; Sabourin JC; Artru P; Tong S; Libert L; Audhuy F; Gicquel C; Moureau-Zabotto L; Ossendza RA; Laurent-Puig P; Ducreux M
Dig Liver Dis; 2018 May; 50(5):507-512. PubMed ID: 29396127
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutations: analytical considerations.
Herreros-Villanueva M; Chen CC; Yuan SS; Liu TC; Er TK
Clin Chim Acta; 2014 Apr; 431():211-20. PubMed ID: 24534449
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
20. Assessing Oncologists' Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data.
Iyer P; Deng M; Handorf EA; Nakhoda S; Dotan E
JNCI Cancer Spectr; 2022 Nov; 6(6):. PubMed ID: 36149298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]